These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23149871)

  • 1. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
    Sarashina A; Koiwai K; Seman LJ; Yamamura N; Taniguchi A; Negishi T; Sesoko S; Woerle HJ; Dugi KA
    Drug Metab Pharmacokinet; 2013; 28(3):213-9. PubMed ID: 23149871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
    Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
    Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Scheen AJ
    Clin Pharmacokinet; 2014 Mar; 53(3):213-225. PubMed ID: 24430725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.
    Kasahara-Ito N; Fukase H; Ogama Y; Saito T; Ohba Y; Shimada S; Takano Y; Ichihara T; Terao K; Nakamichi N; Kumagai Y; Ikeda S
    Drug Res (Stuttg); 2017 Jun; 67(6):349-357. PubMed ID: 28427104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
    Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
    Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
    Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
    Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
    Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
    Heise T; Seman L; Macha S; Jones P; Marquart A; Pinnetti S; Woerle HJ; Dugi K
    Diabetes Ther; 2013 Dec; 4(2):331-45. PubMed ID: 23838841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
    Riggs MM; Seman LJ; Staab A; MacGregor TR; Gillespie W; Gastonguay MR; Woerle HJ; Macha S
    Br J Clin Pharmacol; 2014 Dec; 78(6):1407-18. PubMed ID: 24964723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
    Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
    BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
    Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
    Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
    Ring A; Brand T; Macha S; Breithaupt-Groegler K; Simons G; Walter B; Woerle HJ; Broedl UC
    Cardiovasc Diabetol; 2013 Apr; 12():70. PubMed ID: 23617452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.